High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma
- Rui Liao†1, 2,
- Jian Sun†1, 2,
- Han Wu1, 2,
- Yong Yi1, 2,
- Jia-Xing Wang1, 2,
- Hong-Wei He1, 2,
- Xiao-Yan Cai1, 2,
- Jian Zhou1, 2,
- Yun-Feng Cheng3,
- Jia Fan1, 2 and
- Shuang-Jian Qiu1, 2, 3Email author
© Liao et al.; licensee BioMed Central Ltd. 2013
Received: 28 November 2012
Accepted: 7 January 2013
Published: 11 January 2013
Hepatocellular carcinoma (HCC) is a typical malignancy in a background of chronic inflammation. Th17 cells (a major source of IL-17) constitute crucial components of infiltrating inflammatory/immune cells in HCC and can amplify inflammatory response via binding to interleukin-17 receptor (IL-17R). Thus, we investigated the expression and clinical significance of IL-17 and IL-17 receptor family cytokines in HCC.
The expression and prognostic value of IL-17 and IL-17R (A-E) were examined in 300 HCC patients after resection. Six Th17 associated cytokines in serum (n = 111) were quantified using enzyme-linked immunosorbent assays. Phenotypic features of IL-17+ CD4+ T cells were determined by flow cytometry analysis.
High expression of intratumoral IL-17 and IL1-7RE were significantly associated with poorer survival (p = 0.016 and <0.001, respectively) and increased recurrence (both P < 0.001) of HCC patients. Moreover, intratumoral IL-17, individually or synergistically with IL-17RE, could predict HCC early recurrence and late recurrence. Also, peritumoral IL-17RE showed the prognostic ability in HCC (P < 0.001 for OS/TTR). Furthermore, expression levels of Th17 associated cytokines including IL-6, -22, -17R and TNF-α were increased in serum of HCC patients compared to haemangioma patients. Importantly, activated human hepatic stellate cells induced in vitro expansion of IL-17+ CD4+ T cells.
High expression of IL-17 and IL-17RE were promising predictors for poor outcome of HCC patients. The protumor power of IL-17 producing CD4+ T cells was probably involved in the crosstalk with different types of inflammatory/immune cells in HCC.
Hepatocellular carcinoma (HCC) is a typical malignancy that slowly unfolds on a background of chronic inflammation mainly due to exposure to hepatitis viral infection and cirrhosis . Thus, to a large extent, HCC metastatic biologic behavior and poor prognosis may be determined and/or influenced by the local inflammatory status . We have previously demonstrated that the densities of tumor-associated macrophages , neutrophils  and regulatory T cells  were selectively associated with poor prognosis of HCC patients. Moreover, some inflammatory/immune cells may cooperate with each other to acquire more potent tumor-promoting activities and result in poorer prognosis, such as combination of peritumoral mast cells and T-regulatory cells . Notably, some inflammatory cytokines expression levels like interleukin-2, -15  and −17 , predominantly produced by Th1, Th2 and Th17, are associated with HCC recurrence and survival. These results supported that “context” of inflammation had a potential shift from pro-inflammatory response toward tumor-promoting direction.
A subset of IL-17 producing CD4+ T cells (Th17), preferentially producing IL-17A, IL-17F and IL-22 [8, 9], have been recently appreciated as important regulators in human tumors . However, the protumoral or antitumoral activity of Th17 cells remained controversial [11, 12]. Indeed, collective evidence suggested that the confusing Th17 cells function in tumor arose from the effect of IL-17 itself, which may depend on different tumor microenvironments in various tumor type, location and stage of disease [12, 13]. In HCC, increased IL-17-producing cell infiltrations have been demonstrated to correlate with poor prognosis . A series of data indicated IL-17 could promote tumor progression through neutrophil recruitment [14, 15] and targeting tumor cells directly to activate some signaling pathways such as AKT  and NF-κB . A recent study  revealed that Th17 cells were implicated in a fine-tuned collaborative action with activated monocytes toward a tumor-promoting direction in HCC. Considering IL-17 receptor (IL-17R) is expressed ubiquitously on all types of liver cells , IL-17 producing cells were most likely involved in the crosstalk with various liver-resident cells in HCC. Interestingly, our conjecture was partly supported by a report that IL-17 producing cells could process in a paracrine manner by surrounding IL-17 receptor-positive cells such as hepatic stellate cells (HSCs) . But so far, only limited attention has been paid on the effects of resident inflammatory/immune cells on IL-17 producing cells in HCC. Also, clinical relationships of IL-17 and IL-17 receptor family cytokines in HCC are still unknown.
In this study, we demonstrated high expression of IL-17 and IL-17RE were promising predictors for poor outcome of HCC after resection, and activated human HSCs induced in vitro expansion of IL-17 producing CD4+ T cells, therefore indicating the intrinsic association among various inflammatory/immune cells and cytokines involved in the progress of tumor.
Materials and methods
Patients and specimens
Peritumoral and intratumoral IL-17RE expression according to characteristics of 300 HCC patients
n = 176
n = 124
n = 221
n = 79
Tissue microarray design and immunocytochemistry
TMAs were constructed as described previously . All patients were monitored postoperatively until January 2012. The total numbers of positive cells of each core were evaluated by two independent investigators blind to clinical outcome and knowledge of the clinicopathologic data. Positive staining cells were screened (100X) and four most representative areas were observed (400X) to count using a Leica DMLA light microscope (Leica Microsystems, Wetzlar, Germany). Data were expressed as the mean (±SE) number cells for one computerized 400X microscopic field based on the triplicate samples obtained from each patient.
Immunohistochemistry of paraffin sections was carried out using streptavidin peroxidase conjugated method as described previously . Briefly, primary antibodies were added on the slides to incubate at 4°C overnight. After washing with phosphate buffered solution (PBS) for three times, secondary antibodies were incubated at 37°C for 1 hour. Following incubation with streptoavidin-labeled horseradish peroxidase at room temperature for 30 minutes, tissues were stained with DAB chromogenic agent under light microscope. Antibodies of IL-17 and IL-17R (A-E) were used (R&D Systems and Sigma-Aldrich, dilution from 1:50–200).
Enzyme-linked immunosorbent assay (ELISA) in serum
IL-6, -9, -17, -22, -17R and TNF-α levels in serum were determined using ELISA kits (IL-6, -17 and TNF-α, R&D Systems; IL-9 and 22, eBioscience; IL-17R, RayBio) according to the manufacturers’ instructions.
Isolation and culture of cells
As described previously , peripheral blood mononuclear cells were isolated from the blood of 12 HCC patients and 10 haemangioma patients by LymphoPrep™ (Axis-Shield) gradient centrifugation as described previously , and cultured in RPMI1640 containing 10% fetal calf serum and 1% penicillin/streptomycin.
Activated human hepatic stellate cells (HSCs) were isolated from peritumoral hepatic tissues at distances of 1 cm from the tumor margin as our described previously  and cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal calf serum and 1% penicillin/streptomycin. Briefly, after combined digestion of liver tissue with pronase, collagenase and DNase, HSCs were separated from other nonparenchymal cells by centrifugation over a gradient of 11% Nycodenz (Axis-shield) at 1400g for 20 minutes. Average yield per isolation were 1 × 107 HSCs/20g liver. HSCs purity was assessed by the autofluorescence property and morphology, the populations were more than 90% pure and 95% viable. After passage, activated HSCs purity was 100%, assessed by α-SMA staining. Activated HSCs were studied between serial passages 3 and 6.
Preparation of conditioned medium (CM) and flow cytometry analysis
Conditioned medium (CM) of HSCs was collected as described previously . Briefly, after seeding into T25 flasks (0.6×106 cells/5ml) for 24 hours, HSCs were washed twice with serum-free RPMI1640, and then incubated for another 24 hours with serum-free RPMI1640.CM was then collected, centrifuged to remove cell debris, filtered, and stored at −20°C until use.
5×105 peripheral lymphocytes were cultured in a 24-well plate and resuspended in a 1:1 mixture of fresh CM of HSCs or control medium (RPMI1640 with 5%FBS). After a proliferation time of 7 days with CM of HSCs or control medium, and IL-6 and TGF-β stimulation in the presence of 2 mg/ml anti-CD3 and 1 mg/ml anti-CD28 [22, 23], cells were washed twice with PBS. Then, the peripheral lymphocytes were detected followed by 5 hours stimulation with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) and 500 ng/ml Ionomycin (Sigma) in the presence of 0.7 ul/ml GolgiStop™ (BD Biosciences). Thereafter, cells were stained with surface markers, fixed and permeabilized, and stained with intracellular marker. Finally, cells were fixed with 4% paraformaldehyde for flow cytometry analysis. The fluorochrome-conjugated antibodies used (FITC-conjugated CD4, BD Pharmingen; PE-conjugated CD3 and APC-conjugated IL-17A from eBioscience).
Statistical analysis was completed with SPSS 16.0 (SPSS, Inc., Chicago, IL) and P < 0.05 was considered statistically significant. The Student t test, Fisher’s exact tests, χ2 tests and Spearman ρ coefficients tests were used as appropriate for the comparison of variables. Univariate analysis and multivariate Cox proportional hazards model was performed to estimate independent prognostic factors. The “minimum p value” approach  was used to get an optimal cut-off by X-tile 3.6.1 software (Yale University, New Haven, CT, USA).
Immunohistochemical characteristics of IL-17 receptor family members in HCC
Identification of prognostic cytokines from IL-17 receptor family members and IL-17
Prognostic factors for survival and recurrence
HR (95% CI)
HR (95% CI)
AFP(ng/ml) (≤20 v >20)
Tumor number (single v multiple)
Vascular invasion (yes v no)
Tumor size(cm) (≤5.0 v >5.0)
TNM stage (I v II- III)
Peritumoral density (low v high) IL-17RE
Intratumoral density (low v high)
Combination of IL-17RE &IL-17
Association of IL-17RE/IL-17 with clinicopathologic variables and univariate and multivariate analyses of the prognostic abilities
Prognostic factors for early and late recurrence
HR (95% CI)
HR (95% CI)
AFP(ng/ml)(≤20 v >20)
Tumor size(cm) (≤5.0 v >5.0)
Vascular invasion(yes v no)
TNM stage (I v II- III)
Peritumoral density (low v high) IL-17RE
Intratumoral density (low v high)
Combination of IL-17RE &IL-17
Expression levels of IL-6, -22, -17R and TNF-α were increased in serum of patients with HCC
Conditioned medium of peritumoral activated human HSCs induced expansion of circulating of IL-17 producing CD4+ T cells
Recent attention has been paid to the prognostic ability and underlying molecular mechanisms of IL-17 producing cells to foster growth and progression of HCC [8, 14]. However, research defining the relationships of IL-17 receptor family members and HCC has lagged. In the present study, we observed various expression patterns of IL-17 receptor family members in HCC tissues using immunohistochemistry, which probably suggested their distinct biological effects on tumor growth. Among these receptors, expression levels of IL-17RE exhibited specificity in prognostic ability for dismal outcome of patients with HCC. Compared to low subgroup, patients with high-density of IL-17RE have shorter OS and TTR in both intratumoral and peritumoral tissues. Therefore, patients with high density of IL-17RE need a close monitoring. IL-17RE may provide us a novel prognosticator for poor outcome of HCC patients after surgery.
High expression of intratumoral IL-17 was also related to the prognosis of HCC patients in this cohort, which drove us to investigate its correlation with IL-17RE. Combination of intratumoral IL-17RE and IL-17 densities yielded better predictive performance than them alone. These findings indicated intratumoral IL-17RE and IL-17 may be involved in a fine-tuned collaborative action in the procession of HCC. Although IL-17RE is the least well characterized cytokine of the IL-17 receptor family cytokines, a recent study  reported that IL-17RE could form heterodimeric complex with IL-17RA participating in induction of proinflammatory cytokines and chemokines. We therefore assumed that intratumoral IL17RE had a high degree of functional overlap with IL-17 producing cells and was responsible for aggressiveness of HCC cells, at least in form of heterodimeric complex with IL-17RA. Importantly, we documented that combination of intratumoral IL-17 and IL-17RE densities were associated with HCC recurrences which can be divided into early recurrence (≤24 months), a true metastasis caused by dissemination of cancer cells, and late recurrence (>24 months) originating from de novo hepatocarcinogenesis . In this study, we proposed that IL-17 and IL-17RE orchestrated the protumor activities in the procession of HCC recurrence and progression due to the residual intrahepatic metastases as well as de novo cancer in the liver remnant.
In addition to the local immune response in liver tissue, expression levels of considerable soluble factors in circulation may reflect the systemic immune status of individuals with tumor and act as noninvasive markers for HCC screening and recurrence monitoring . So, we evaluated the serum levels of Th17 associated cytokines/inflammatory mediators and found higher levels of IL-6, -17RA, -22 and TNF-α in HCC than those in haemangioma, suggesting their potential value as monitoring indictors in HCC. During inflammatory response, TNF-α and IL-17 can act in a synergistic manner to sustain neutrophil recruitment . Recent evidence  found that IL-17 could enhance IL-6 production and subsequently promote tumor growth. On the other hand, IL-6 and IL-9 were critical initiators of Th17 differentiation and expansion which facilitate IL-17 secretion [29, 30]. Interestingly, IL-22 has already been identified as a coexpression cytokine with IL-17 in Th17 cells and cooperatively induced an innate immune response . Thus, we proposed that distinct expression levels of these cytokines may reflect their potential immune regulatory properties and synergistic interactions of cytokine networks in part via IL-17 signaling pathway. Moreover, the kinetics of cytokine products may serve as critical homeostatic factors in inflammatory “context” to determine the direction of tumor progression to some extent. In the present study, IL-17 expression level was not increased significantly. We speculated that compared with the circulating factors, fertile liver tissues (soil) endowed with abundant activated inflammatory/immune cells may play a more important role to determine IL-17 as a protumoral component. Obviously, numerous cytokines or growth factors involved in IL-17 pathway also need to be investigated such as IL-1, IL-23, TGF-β. In the absence of commercial human IL-17RE ELISA kit, we did not detect its expression in serum. Further study is required in our future research.
Despite several substantive studies [10, 17] have confirmed the crosstalk with several types of inflammatory/immune cells contributed to the protumor power of Th17 (a major source of IL-17), knowledge of their interaction in HCC is still incomplete. In a recent study , we demonstrated HSCs were the vital inflammatory cells involved in the recurrence of HCC and could produce cytokines (IL-6 and TNF-α) to create a cytokine milieu that benefited the expansion of human Th17 cells . Moreover, our recent gene expression profile of HSCs confirmed several IL-17 receptors (e.g. IL-17RA, RB and RE) were expressed in HSCs (data not shown). Inasmuch as the function of HSCs as liver-resident antigen-presenting cells , we identified the phenotypic features of IL-17 producing CD4+ T cells with the influence of HSCs in vitro. Interestingly, our present investigation provided evidence that secretions of activated human HSCs induced in vitro expansion of IL-17+ CD4+ T cells in HCC. In contrast, a recent data indicated suppressing Th17 differentiation by mouse HSCs . Several aspects may contribute to this discrepancy. The first could be the different species (human vs mouse). Second, we used conditioned medium of HSCs, not per se HSCs, in order to eliminate the effects of other T cells on HSCs and subsequently feedback responses. Third, activation of HSCs can led to the loss of retinoic acid (RA)  which has already been identified as a key regulator to inhibit the generation of Th17 . Therefore, absence of RA and in vitro activation made human HSCs appear to be fibroblast-like cells which were addressed to promote the expansion of Th17 . Most recently, we found TREM-1 was a pro-tumor gene in HSCs , however, two independent studies on human gene expression profile displayed its contradictory roles in development of T cells: enhancing Th1 priming in mature dendritic cells  and dampening Th1 and Th17 responses in monocytes . Therefore, the same gene in different cells appears to bias certain function toward an alternatively activated phenotype, suggesting the mechanistic complexity in signal integration of functional genes in various cells. A detailed understanding needs to be investigated.
In this study, we only studied some representative inflammatory mediators and the blood sample size was not large. Additionally, response to the stimulation of activated HSCs, the roles of memory and naïve CD4+ T cells in expansion of IL-17+ cells should be different. Various synergistic effects from other T cells or secretions in PBMC may participate in this process. We believe there are more linkages between activated HSCs, IL-17 and their receptors than what involved in this study. Therefore, extensive studies are needed in the future.
In conclusion, we have shown that the high expression of IL-17 and IL-17RE in HCC were associated with worse clinical outcome after resection. The protumor power of IL-17 producing CD4+ T cells was probably involved in the mechanisms of inflammatory response interacting with different types of inflammatory/immune cells in HCC. In this regard, IL-17 and IL-17RE, acting as tumor promoters, may provide useful predictors for triaging at-risk patients with recurrence and metastasis of HCC following resection and also possible therapeutic targets against this disease.
This work was supported by the National Key Sci-Tech Special Project of China (Nos. 2012ZX10002010-001-002), National Natural Science Foundation of China (Nos. 81071707 and 81071995; key program No. 81030038), the Open Project of the State Key Laboratory of Oncogene and Related Gene (No.90-09-03), Doctoral Fund of the Ministry of Education of China (No. 200802460019).
- Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006, 6: 674-687. 10.1038/nrc1934.View ArticleGoogle Scholar
- Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, et al.: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006, 10: 99-111. 10.1016/j.ccr.2006.06.016.View ArticleGoogle Scholar
- Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008, 26: 2707-2716. 10.1200/JCO.2007.15.6521.View ArticleGoogle Scholar
- Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011, 54: 497-505. 10.1016/j.jhep.2010.07.044.View ArticleGoogle Scholar
- Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007, 25: 2586-2593. 10.1200/JCO.2006.09.4565.View ArticleGoogle Scholar
- Ju MJ, Qiu SJ, Gao Q, Fan J, Cai MY, Li YW, Tang ZY: Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci. 2009, 100: 1267-1274. 10.1111/j.1349-7006.2009.01182.x.View ArticleGoogle Scholar
- Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, Liu Y, Ye Q, Sun H, Zhu X, et al.: Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut. 2010, 59: 1699-1708. 10.1136/gut.2010.218404.View ArticleGoogle Scholar
- Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009, 50: 980-989. 10.1016/j.jhep.2008.12.033.View ArticleGoogle Scholar
- Iwakura Y, Ishigame H, Saijo S, Nakae S: Functional specialization of interleukin-17 family members. Immunity. 2011, 34: 149-162. 10.1016/j.immuni.2011.02.012.View ArticleGoogle Scholar
- Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009, 206: 1457-1464. 10.1084/jem.20090207.View ArticleGoogle Scholar
- Bronte V: Th17 and cancer: friends or foes?. Blood. 2008, 112: 214-View ArticleGoogle Scholar
- Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W: Th17 cells in cancer: help or hindrance?. Carcinogenesis. 2011, 32: 643-649. 10.1093/carcin/bgr019.View ArticleGoogle Scholar
- Zou W, Restifo NP: T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010, 10: 248-256. 10.1038/nri2742.View ArticleGoogle Scholar
- Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z, et al.: IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer. 2011, 10: 150-10.1186/1476-4598-10-150.View ArticleGoogle Scholar
- Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J, et al.: Intratumoral IL-17(+) Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2012, 19: 2506-2514. 10.1245/s10434-012-2268-8.View ArticleGoogle Scholar
- Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY: Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One. 2011, 6: e21816-10.1371/journal.pone.0021816.View ArticleGoogle Scholar
- Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L: Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010, 51: 154-164. 10.1002/hep.23291.View ArticleGoogle Scholar
- Lafdil F, Miller AM, Ki SH, Gao B: Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol. 2010, 7: 250-254. 10.1038/cmi.2010.5.View ArticleGoogle Scholar
- Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, De Nadai P, Geerts A, Quertinmont E, Vercruysse V, et al.: The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009, 49: 646-657. 10.1002/hep.22680.View ArticleGoogle Scholar
- Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang JX, Zhou J, Shi YH, Cheng YF, Qiu SJ, et al.: Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Cancer Sci. 2012, 103: 984-992. 10.1111/j.1349-7006.2012.02273.x.View ArticleGoogle Scholar
- Liao R, Liu Z, Wei S, Xu F, Chen Z, Gong J: Triggering receptor in myeloid cells (TREM-1) specific expression in peripheral blood mononuclear cells of sepsis patients with acute cholangitis. Inflammation. 2009, 32: 182-190. 10.1007/s10753-009-9119-1.View ArticleGoogle Scholar
- Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, Yin XY, Li L, Zheng L: Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol. 2010, 185: 1544-1549. 10.4049/jimmunol.0904094.View ArticleGoogle Scholar
- Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H: Hepatic stellate cells function as regulatory bystanders. J Immunol. 2011, 186: 5549-5555. 10.4049/jimmunol.1003917.View ArticleGoogle Scholar
- Gaffen SL: Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009, 9: 556-567. 10.1038/nri2586.View ArticleGoogle Scholar
- Vinas O, Bataller R, Sancho-Bru P, Gines P, Berenguer C, Enrich C, Nicolas JM, Ercilla G, Gallart T, Vives J, et al.: Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology. 2003, 38: 919-929.View ArticleGoogle Scholar
- Song X, Zhu S, Shi P, Liu Y, Shi Y, Levin SD, Qian Y: IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 2011, 12: 1151-1158. 10.1038/ni.2155.View ArticleGoogle Scholar
- Spangenberg HC, Thimme R, Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006, 26: 385-390. 10.1055/s-2006-951606.View ArticleGoogle Scholar
- Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V, Alcaide P, Grabie N, Luscinskas FW, Croce KJ, et al.: IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol. 2012, 188: 6287-6299. 10.4049/jimmunol.1200385.View ArticleGoogle Scholar
- Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27: 485-517. 10.1146/annurev.immunol.021908.132710.View ArticleGoogle Scholar
- Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, Van Snick J, Renauld JC, et al.: IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA. 2009, 106: 12885-12890. 10.1073/pnas.0812530106.View ArticleGoogle Scholar
- Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006, 203: 2271-2279. 10.1084/jem.20061308.View ArticleGoogle Scholar
- Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH: Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity. 2007, 26: 117-129. 10.1016/j.immuni.2006.11.011.View ArticleGoogle Scholar
- Ohata M, Lin M, Satre M, Tsukamoto H: Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis. Am J Physiol. 1997, 272: G589-G596.Google Scholar
- Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007, 317: 256-260. 10.1126/science.1145697.View ArticleGoogle Scholar
- Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G: Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010, 184: 1630-1641. 10.4049/jimmunol.0902813.View ArticleGoogle Scholar
- Bosco MC, Pierobon D, Blengio F, Raggi F, Vanni C, Gattorno M, Eva A, Novelli F, Cappello P, Giovarelli M, et al.: Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood. 2011, 117: 2625-2639. 10.1182/blood-2010-06-292136.View ArticleGoogle Scholar
- Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol. 2008, 180: 3520-3534.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.